| abstract |
The present invention particularly relates to pharmaceutically acceptable compositions comprising metirapol as the sole pharmaceutically active agent; A composition comprising metirapol and one or more additional pharmaceutical actives; Known reconsiderations by conjugation to the agent itself that targets the HPA axis itself is novel or modified (e.g., a bispecific antibody designed to cross the blood-brain barrier, or a substance that crosses the blood-brain barrier, for example) Compounds) compositions; And compositions that are newly formulated in such a way that agents targeting the HPA axis do not significantly inhibit cortisol production in the adrenal glands. For example, the composition may be formulated to include doses that are too low to reduce plasma cortisol levels or may be formulated to preferentially affect the skin. |